Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 5 recruiting now early-phase tilt small index

Drug Resistant Epilepsy: early-phase trial registry

5 of 7 indexed Drug Resistant Epilepsy trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,497 of 28,707 conditions by registered trial count.

7 US clinical trials · 5 currently recruiting · #2,497 of 28,707 conditions by registered trial count

Drug Resistant Epilepsy: 7 US clinical trials tracked, 5 recruiting.

Drug Resistant Epilepsy is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Michael A. Gelfand, MD, PhD, running 1 of these trials.

Enrollment posture brief

Registry condition drug-resistant-epilepsy

OPEN 5 | RECR 71% | LATE 0 | EARLY 2 | RANK #2497 | SPON 1

Nearest open-share peer: Advanced Endometrial Carcinoma (71% recruiting · 7 trials)

ACL Tear71.4%Drug Resistant Epilepsy (thi…71%ACL57.1%Acute Myelogenous Leukemia42.9%Acne Scars28.6%
Open-enrollment share among volume-matched conditions near Drug Resistant Epilepsy

Drug Resistant Epilepsy lists 5 open slots (71% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Drug Resistant Epilepsy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Drug Resistant Epilepsy is recruiting above its size-band peers.

    5 of 7 indexed trials (71.4%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Drug Resistant Epilepsy trials is spread across many organizations.

    Michael A. Gelfand, MD, PhD accounts for 1 of 7 trials (14.3%). 7 distinct sponsors appear on at least one study for this condition label.

  3. Most Drug Resistant Epilepsy trials plan to enrol fewer than 100 people.

    Median target enrolment is 10 among the 7 trials that report a genuine target (sentinel values excluded). 6 of those (85.7%) plan for fewer than 100 participants.

  4. Drug Resistant Epilepsy research is mostly interventional.

    7 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 21

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 1

Named interventions

Most-linked intervention names on Drug Resistant Epilepsy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Hövding inflatable helmet Device
1 trials
Stereoelectroencephalography Behavioral
1 trials
NaviFUS System Device
1 trials
Questionnaires for Providers Behavioral
1 trials
Epilepsy Visit Planner Behavioral
1 trials
Survey questionnaires Behavioral
1 trials
photobiomodulation Device
1 trials
Focused ultrasound Device
1 trials

US sites by state

Facility locations filed on Drug Resistant Epilepsy trials. A trial with sites in several states counts in each.

Massachusetts 3 trials
New York 2 trials
Virginia 1 trials
Pennsylvania 1 trials
Michigan 1 trials
California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Drug Resistant Epilepsy page

7 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Drug Resistant Epilepsy condition card totals 7 registered trials; most-linked intervention Hövding inflatable helmet; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.